Drug class in one race
CXCR4 drugs for Multiple Myeloma
4 tracked CXCR4 drugs in the Multiple Myeloma race. The class explanation lives on the CXCR4 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
2 approved / phase 42 Phase 2
Head-to-head evidence: Burixafor (TG-0054) vs GPC-100 · Burixafor (TG-0054) vs Motixafortide · Burixafor (TG-0054) vs Plerixafor · GPC-100 vs Motixafortide · GPC-100 vs Plerixafor · Motixafortide vs Plerixafor